A COVID-19 diagnosis is no longer as frightening as it used to be, thanks to developments in treatment choices. However, a new study reveals that leukocyte (white blood cell) count may now be used to identify who is more likely to develop more significant disease symptoms.
“As the authors highlight, post-acute sequelae of severe acute respiratory coronavirus 2 infection significantly affects quality of life, often leading to severe disability. This effect is particularly pronounced in women, who already experience higher rates of cognitive impairment after menopause. By understanding underlying factors, we can better address these challenges and work to mitigate the cascade of symptoms that follow,” says Dr Monica Christmas, associate medical director for The Menopause Society.
Millions of people worldwide suffer from the ongoing effects of Covid-19–which is caused by the SARs-CoV-2 virus–even months after the initial diagnosis. Cognitive impairment and fatigue are the most common lingering symptoms, with cognitive impairment affecting 70 per cent of patients. Older adults–especially women–are the most at risk.
Although healthcare professionals know a lot more about Covid-19 than they did at the start of the pandemic in 2020, there are still many lingering questions regarding its effect on the human body. Although it is primarily a respiratory disease, sustained effects on multiple organ systems have been documented. Previous studies have shown an excessive immune response to a Covid-19 infection.
Researchers in this latest study, based on secondary analysis of data from the Women’s Health Initiative, sought to better understand preexisting risk factors that may make certain adults–especially older postmenopausal women–more vulnerable to more serious ongoing symptoms. Specifically, they examined whether leukocyte count (a widely available clinical marker of systemic inflammation) was associated with COVID disease outcomes.
Based on the results, the researchers concluded that leukocyte count is an independent predictor of COVID symptom severity in postmenopausal women. These results extend the evidence that low-grade inflammation is not only an outcome of COVID symptom severity but may also precede the acute Covid-19 infection. Additional research in this area is necessary, but the initial work is promising because leukocyte count represents an easily accessible, inexpensive clinical marker.
(with inputs from ANI)
Comments